BI 3032950

DRUG3 trials

Sponsors

Boehringer Ingelheim International GmbH, Boehringer Ingelheim

Conditions

Healthyulcerative colitits

Phase 1

A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated

CompletedNCT05518708

Boehringer IngelheimHealthy

Start: 2022-09-27End: 2023-09-21Updated: 2023-09-26

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

CompletedNCT05985200

Boehringer IngelheimHealthy

Start: 2023-09-15End: 2024-08-19Updated: 2024-11-21

Phase 2

Phase IIa, single-arm, open-label, multi-center clinical trial to evaluate the efficacy, safety, and tolerability of intravenous induction and subcutaneous maintenance treatment with BI 3032950 in patients with moderate to severe ulcerative colitis

Active, not recruitingCTIS2023-509544-10-00

Boehringer Ingelheim International GmbHulcerative colitits

Start: 2025-01-15Target: 56Updated: 2025-11-26